关键词: 子宫内膜癌, 晚期子宫内膜癌, 新辅助化疗

Abstract: Endometrial cancer is a common malignant tumor of female malignant tumors and its incidence is increasing in recent years. About 80%-90% of EC patients are in the early stage. In the early stage of EC，surgery is the main treatment，and adjuvant radiotherapy or chemotherapy is performed according to the risk factors after surgery. The 5-year survival rate is more than 80%. However，the 5-year survival rate is only 15% for patients with advanced EC. For advanced patients with limited methods of treatment，surgery，chemotherapy，radiotherapy and other comprehensive treatment methods are used. Similar to advanced ovarian cancer，maximum cytoreductive surgery for advanced EC is associated with prognosis. Patients with stage Ⅲ/Ⅳ EC，if surgery is available，should undergo maximum tumor reduction to achieve no residual lesions as far as possible. However，for patients with systemic multiple metastases and contraindications，neoadjuvant chemotherapy（NACT）is the preferred option followed by surgery，which is aimed at improving tumor resection rate and reducing surgical complications. NACT for advanced endometrial cancer include chemotherapy agents，immunotherapy，antiangiogenic therapy，targeted therapy，and hormonal therapy. This article reviews the relevant studies of NACT in the treatment of advanced endometrial cancer，in order to understand the application status of NACT in advanced EC and provide reference for clinical diagnosis and treatment.

Key words: endometrial cancer, advanced endometrial cancer, neoadjuvant chemotherapy